Prasugrel hydrochloride is an anti-platelet agent.
It is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome (i.e., unstable angina, non-ST segment elevation myocardial infarction [UA/NSTEMI] or ST segment elevation myocardial infarction [STEMI]) undergoing primary or delayed percutaneous coronary intervention (PCI).
It is formulated as tablets and film-coated tablets for oral route of administration.
Mechanism of action:
Prasugrel is a P2Y purinoceptor 12 (P2Y12) inhibitor. It acts through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets. This impairs the ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. This causes inactivation of platelets and blocks blood clotting.